A5006179968- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Adrenal and Paraganglionic Tumors
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
- Cancer, Hypoxia, and Metabolism
- Testicular diseases and treatments
- Organ Donation and Transplantation
- Colorectal Cancer Surgical Treatments
- Multiple and Secondary Primary Cancers
- Cancer, Lipids, and Metabolism
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Renal and Vascular Pathologies
- Urinary Tract Infections Management
- Hormonal and reproductive studies
- Pituitary Gland Disorders and Treatments
- Venous Thromboembolism Diagnosis and Management
Japanese Foundation For Cancer Research
2010-2025
Chiba University
2023-2024
Cancer Institute (WIA)
2009-2024
National Cancer Center Hospital East
2013-2022
The Cancer Institute Hospital
2007-2021
Tokyo Medical and Dental University
2004-2018
Tokyo Medical and Dental University Hospital
2008
Tsuchiura Kyodo General Hospital
2004-2006
Okayama University
1978
Abstract Purpose: To determine the incidence of Xp11 translocation renal cell carcinoma (RCC) in adult patients using cytogenetics and immunohistochemstry. Experimental Design: Cytogenetic studies were prospectively done tumor samples from 443 consecutive Japanese (ages 15-89 years) who underwent nephrectomy for RCC. TFE3 immunohistochemistry was cases which cytogenetic results not obtained. Clinicopathologic characteristics RCC examined. Results: Mitotic cells suitable analysis obtained 244...
C-reactive protein has been shown to be a prognostic factor for renal cell carcinoma. We developed new prediction model including in patients with clear carcinoma.This study is based on 2 cohorts of Japanese carcinoma, 249 evaluating factors and developing the model, 290 external validation. Analyzed included TNM classification, tumor size, Fuhrman nuclear grade, necrosis preoperative serum (cutoff 0.5 mg/dl). scoring multivariate analysis predict cancer specific survival. Predictive ability...
No AccessJournal of UrologyAdult Urology1 Sep 2013High Diagnostic Ability Multiparametric Magnetic Resonance Imaging to Detect Anterior Prostate Cancer Missed by Transrectal 12-Core Biopsy Yoshinobu Komai, Noboru Numao, Soichiro Yoshida, Yoh Matsuoka, Yasukazu Nakanishi, Chikako Ishii, Fumitaka Koga, Kazutaka Saito, Hitoshi Masuda, Yasuhisa Fujii, Satoru Kawakami, and Kazunori Kihara KomaiYoshinobu Komai More articles this author , NumaoNoboru Numao YoshidaSoichiro Yoshida MatsuokaYoh...
We evaluated the usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to decrease initial prostate biopsies.We prospectively 351 consecutive men with specific antigen between 2.5 20 ng/ml, and/or digital rectal examination suspicious for clinically localized disease. All underwent 14 29-core biopsy, including anterior sampling. Three definitions significant cancer were defined based on Gleason score volume (percent positive core maximum length). The...
To evaluate the value of preoperative serum C-reactive protein (CRP) level in prognosis patients with localized renal cell carcinoma (RCC).The study comprised 101 who had a radical nephrectomy for RCC (pT1-3N0M0). An elevated CRP was defined as >0.5 mg/dL before surgery. Survival rates each variant were calculated using Kaplan-Meier method, difference between survival curves evaluated log-rank test. Multivariate analysis by Cox proportional hazard model; all analyses considered significant...
This analysis utilized a subject-based of data from the prospective single-arm phase III trial (jRCT2061210055) to evaluate efficacy photodynamic diagnosis (PDD) when 5-aminolevulinic acid hydrochloride (5-ALA) was administered 4-8 h before transurethral resection bladder tumors (TURBT). study evaluated 144 patients suspected having non-muscle invasive cancer (NMIBC), including 127 with NMIBC (38 had normal-to-flat-appearing cancer) and 17 without cancer. The diagnostic accuracy clinical...
To determine the diagnostic accuracy of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for detecting metastasis and its impact on patient management with upper tract urothelial carcinoma (UTUC).Consecutive patients UTUC underwent 18F-FDG PET/CT after CT initial staging (n = 47) restaging at recurrence 9). Diagnostic metastases was compared statistically. The assessed by comparing questionnaires that were completed attending physicians before...
To assess the impact of C-reactive protein (CRP) kinetics, effect dynamic changes CRP concentration on survival patients with locally advanced or metastatic urothelial carcinoma (UC) treated by single chemotherapeutic regimen including cisplatin was examined.Eighty UC, who failed treatment UC first-line chemotherapy received perioperative neoadjuvant adjuvant settings, were gemcitabine, etoposide and (GEP) as second-line chemotherapy. Patients divided into three groups according to kinetics...
Pembrolizumab was approved as second-line treatment for patients with metastatic urothelial cancer (UC) in Japan. We performed a retrospective pilot study to assess the potency of pembrolizumab Japan.The medical records 40 consecutive Japanese UC who started between January and October 2018 were reviewed statistically analyzed clarify efficacy safety drug.The objective response rate, median progression-free survival period, overall period 20.6%, 4.1 months 10.0 months, respectively....
To investigate the association of lymphovascular invasion (LVI) in radical prostatectomy (RP) specimens with prostate-specific antigen (PSA) failure patients pT3aN0 prostate cancer (PCA).We retrospectively reviewed clinical records 94 PCA treated RP alone. All were prospectively observed without any treatment until PSA was confirmed. We investigated LVI adverse pathological findings and failure-free survival rate. The Cox proportional hazard model used to elucidate predictors failure.Median...
The paradigm of medical treatment for metastatic urothelial carcinoma is dramatically changing through the introduction pembrolizumab.
Currently, only a few reports exist on the cytokine release syndrome (CRS) as one of severe immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). Notably, it is very rare that grade 4 CRS related to ICI therapy overlaps with drug-induced hypersensitivity (DiHS). A 46-year old woman metastatic kidney cancer had 3 interstitial pneumonitis four cycles combination anti-programmed death-1 and anti-cytotoxic T lymphocyte-4 antibodies after right cytoreductive...
Immune-related adverse events (irAEs) develop in a subset of patients with metastatic renal cell carcinoma (mRCC) treated immune-checkpoint-inhibitors (ICIs). Evidence regarding the prognostic impact irAEs remains limited these patients.Ninety-one consecutive mRCC ICIs were retrospectively analyzed. Overall survival (OS) rates estimated using Kaplan-Meier method. In multivariate analysis, predictors OS analyzed Cox-proportional-hazards-model.Twenty-nine combination nivolumab plus ipilimumab....